First Patient Enrolled in Alenura Study for Interstitial Cystitis


When it comes to treating interstitial cystitis, doctors may take a multipronged approach: physical therapy, bladder distention, surgery, nerve stimulation, oral medications. But people with this condition lack therapies that directly target and treat the associated acute bladder pain. Specialty pharmaceutical companies Hyloris Pharmaceuticals (“Hyloris”) and Vaneltix Pharma, Inc. (“Vaneltix”) are working together to fill this unmet need through developing Alenura. 

Alenura: An Overview

Vaneltix explains that Alenura, which is administered intravesicularly, is a combination therapy using alkalinized lidocaine and glycosaminoglycan heparin. It provides on-demand pain relief for people experiencing painful episodes due to interstitial cystitis. The alkalinized lidocaine works by penetrating the transitional epithelial cell layer, where it reduces inflammation and pain. The heparin stabilizes the alkalinized lidocaine, combats inflammation, and fights germs. So far, Alenura has demonstrated its efficacy on reducing pain in various studies. It also seems safe and well-tolerated.

Launching the Next Phase of Clinical Studies

In a news release from Hyloris, the company shares that the first patient was enrolled in an upcoming clinical trial evaluating Alenura and its individual parts. During the trial, researchers will test heparin, alkalinized lidocaine, Alenura, and a placebo to identify how well Alenura controls and reduces pain comparatively. Altogether, an estimated 120 participants will enroll. 

Interstitial Cystitis: An Overview

Also known as: Bladder pain syndrome

Interstitial cystitis is a chronic bladder condition characterized by pain and pressure. There are two main forms: ulcerative and non-ulcerative, with the latter being significantly more common. It’s still a mystery as to what causes this condition. Doctors believe a number of factors may play a role. You can learn more about these factors from the Interstitial Cystitis Association (ICA). Interstitial cystitis mostly affects females, though males may also be affected. Additional risk factors include having fair skin and/or red hair, being over 30 years old, and having another chronic pain condition. Symptoms vary and may worsen during “flares.” Potential symptoms may include: 

  • Pelvic pain
  • Frequent and urgent urination
  • Painful intercourse
  • Pain or discomfort when that bladder fills that is relieved by urinating
Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Follow us